Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06028932 · ClinicalTrials.gov registry record · Phase 2
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
A Phase 2 study of Ovarian Carcinoma, sponsored by Yale University.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06028932: Active Phase 2 study of Ovarian Carcinoma, sponsored by Yale University.
NCT06028932 is a Phase 2 study of Ovarian Carcinoma that is active but no longer recruiting, run by Yale University. The registered enrollment target is 20 participants, below the 3,244-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06028932, a Phase 2 study of Ovarian Carcinoma, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Primary Outcome
Objective response rate (complete response and partial response rates) by RECIST1.1 criteria in patients with platinum resistant recurrent ovarian carcinoma.
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan
Study Locations (1)
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-01-08 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 2 |
What the registry record for NCT06028932 still lists
NCT06028932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 3,244-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Ovarian Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab govitecan is the first listed.
NCT06028932 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06028932 about?
NCT06028932 is a clinical study titled "A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients". This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
What is the current status of trial NCT06028932?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-01-08. Estimated completion is 2027-11-01.
What conditions does trial NCT06028932 study?
This clinical trial studies the following conditions: Ovarian Carcinoma.
What interventions are being tested in trial NCT06028932?
The interventions under investigation include: Sacituzumab govitecan (DRUG).
Who is sponsoring clinical trial NCT06028932?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06028932 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06028932's enrollment target sits among peer trials
20 33rd of 35 higher than 3 of 35 other Ovarian Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI